{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:42:29Z","timestamp":1778283749558,"version":"3.51.4"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ceftriaxone is highly effective clinically in patients with Lyme disease. We studied a representative invasive human isolate of\n            <jats:italic>Borrelia burgdorferi<\/jats:italic>\n            for which the MBC of ceftriaxone was 0.050 \u03bcg\/ml. A once-per-day dosage regimen of ceftriaxone (50 mg\/kg\/dose) administered intramuscularly for 5 days was 100% effective in sterilizing tissue samples of C3H mice infected with this strain of\n            <jats:italic>B. burgdorferi<\/jats:italic>\n            , regardless of whether the mice were being treated concomitantly with a corticosteroid. Administration of the same five doses of ceftriaxone at 6-h intervals over just 24 h was also 100% effective. These experiments suggest that shorter courses of antibiotics than those currently recommended should be considered for study in patients with early uncomplicated Lyme disease.\n          <\/jats:p>","DOI":"10.1128\/aac.46.1.132-134.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"132-134","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of Short-Course Ceftriaxone Therapy for\n            <i>Borrelia burgdorferi<\/i>\n            Infection in C3H Mice"],"prefix":"10.1128","volume":"46","author":[{"given":"Charles","family":"Pavia","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Departments of Medicine"},{"name":"New York College of Osteopathic Medicine Microbiology and Immunodiagnostic Laboratory of the New York Institute of Technology, Old Westbury, New York 11578"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Mario A.","family":"Inchiosa","sequence":"additional","affiliation":[{"name":"Pharmacology, New York Medical College, Valhalla, New York 10595"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Departments of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"357","volume":"272","year":"1983","unstructured":"Ascalone, V., and L. Dal Bo. 1983. Determination of ceftriaxone, a novel cephalosporin, in plasma, urine and saliva by high-performance liquid chromatography on an NH2 bonded phase column. J. Chromatogr.272:357\u2013366.","journal-title":"J. Chromatogr."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF01780660","volume":"24","year":"1996","unstructured":"Baradaran-Dilmaghani, R., and G. Stanek. 1996. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection24:60\u201363.","journal-title":"Infection"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1333-1336.2000"},{"key":"e_1_3_2_5_2","first-page":"573","volume":"177","year":"1978","unstructured":"Butler, T., P. K. Jones, and C. K. Wallace. 1978. Borrelia recurrentis infection: single-dose antibiotic regimens and management of Jarisch-Herxheimer reaction. J. Infect. Dis.177:573\u2013577.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1766"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.2.164"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2632"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1567"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02013102"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.6.563"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80068-6"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/516168"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.936-937.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/315340"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.10.1932"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1010-1018.2000"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.7.4303-4312.2001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01641422","volume":"18","year":"1990","unstructured":"Weber, K., V. Preac-Mursic, B. Wilske, R. Thurmayr, U. Neubert, and C. Scherwitz. 1990. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection18:91\u201396.","journal-title":"Infection"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/314053","volume":"31","unstructured":"Wormser, G. P., R. B. Nadelman, R. J. Dattwyler, et al. 200 Practice guidelines for the treatment of Lyme disease. Clin. Infect Dis.31(Suppl. 1):S1\u2013S14.","journal-title":"Clin. Infect Dis."},{"key":"e_1_3_2_21_2","first-page":"188","volume":"62","year":"1995","unstructured":"Wormser, G. P. 1995. Lyme disease: insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections. Mt. Sinai J. Med.62:188\u2013195.","journal-title":"J. Med."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1379.","DOI":"10.1093\/infdis\/171.5.1379","volume":"171","year":"1995","unstructured":"Wormser, G. P. 1995. Duration of therapy for Lyme borreliosis. J. Infect. Dis.171:1379.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.39.2.655-658.1983"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.1.132-134.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.1.132-134.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:30:35Z","timestamp":1645464635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.1.132-134.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1128\/AAC.46.1.132-134.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.1.132-134.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"2001-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}